ClinicalTrials.gg

Program

cretostimogene grenadenorepvec

Also written as “Cretostimogene Grenadenorepvec”, “CG0070” and “oncolytic adenovirus expressing GMCSF”.

Its studies are mostly in Non-Muscle Invasive Bladder Neoplasms · Urinary Bladder Neoplasms · Carcinoma, Transitional Cell, led by 3 companies.

Furthest: phase 3, since Jun 26, 20208 company-led studies, 4 open or runningNext primary completion: Nov 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CG Oncology63 open or runningphase 3since Jun 26, 2020May 19, 2014Nov 2026phase 3 · NCT06111235
Cell Genesys10 open or runningphase 1since May 2, 2005May 2, 2005none ahead
Lepu Biopharma11 open or runningphase 2since Dec 6, 2025Dec 6, 2025Dec 31, 2027phase 2 · NCT07283835

Also a collaborator on its studies: Merck.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 2, 2005First study: phase 1 study in Carcinoma, Transitional CellNew to Cell GenesysCell Genesys · NCT00109655 · 75 enrolled · United States, Canada
  2. May 19, 2014CG Oncology's first study: phase 2 study in Urinary Bladder NeoplasmsNew to CG OncologyCG Oncology · NCT02143804 · United States
  3. Feb 9, 2015Phase 2 study in Urinary Bladder NeoplasmsCG Oncology · NCT02365818 · 66 enrolled · United States
  4. May 5, 2020Phase 2 study in Non-Muscle Invasive Bladder NeoplasmsCG Oncology · NCT04387461 · 35 enrolled · United States, Korea, Republic of
  5. Jun 26, 2020Phase 3 study in Non-Muscle Invasive Bladder NeoplasmsCG Oncology · NCT04452591 · 190 enrolled · United States, Australia, Canada and more
  6. Oct 25, 2023Phase 3 study in Non-Muscle Invasive Bladder NeoplasmsCG Oncology · NCT06111235 · 367 enrolled · United States, Canada
  7. Aug 14, 2024Phase 2 study in Urinary Bladder NeoplasmsCG Oncology · NCT06567743 · 325 planned · United States, Canada
  8. Dec 6, 2025Lepu Biopharma's first study: phase 2 study in Non-Muscle Invasive Bladder NeoplasmsNew to Lepu BiopharmaLepu Biopharma · NCT07283835 · 16 planned · China

Ahead

  1. Nov 2026Primary completion: phase 3 study in Non-Muscle Invasive Bladder NeoplasmsCG Oncology · NCT06111235
  2. Mar 31, 2027Primary completion: phase 2 study in Urinary Bladder NeoplasmsCG Oncology · NCT06567743
  3. Dec 31, 2027Primary completion: phase 2 study in Non-Muscle Invasive Bladder NeoplasmsLepu Biopharma · NCT07283835
  4. Jun 16, 2030Primary completion: phase 3 study in Non-Muscle Invasive Bladder NeoplasmsCG Oncology · NCT04452591

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07283835Non-Muscle Invasive Bladder Neoplasms · China2RecruitingLepu BiopharmaDec 31, 202716
NCT06567743Urinary Bladder Neoplasms · United States, Canada2RecruitingCG OncologyMar 31, 2027325
NCT06111235Non-Muscle Invasive Bladder Neoplasms · United States, Canada3Active, not recruitingCG OncologyNov 2026367
NCT04452591Non-Muscle Invasive Bladder Neoplasms · United States, Australia, Canada and more3Active, not recruitingCG OncologyJun 16, 2030190
NCT04387461Non-Muscle Invasive Bladder Neoplasms · United States, Korea, Republic of2CompletedCG OncologyMar 7, 202335
NCT02365818Urinary Bladder Neoplasms · United States2CompletedCG OncologyAug 201866
NCT02143804Urinary Bladder Neoplasms · United States2WithdrawnCG OncologyMar 20150
NCT00109655Carcinoma, Transitional Cell · United States, Canada1UNKNOWNCell GenesysOct 200875

How it is read

Names in the registry

  • “Cretostimogene Grenadenorepvec”, 4 entries
  • “CG0070”, 2 entries
  • “oncolytic adenovirus expressing GMCSF”, 1 entry
  • “Oncolytic adenovirus (serotype 5) - CG0070”, 1 entry

Codes read as this program: CG0070.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.